IL-6、TNF-α与SIgA在COPD急性加重期的临床意义  

The clinical significance of IL-6, TNF-α and SIgA assaying in acute exacerbating COPD

作　　者：王蓉美[1] 李小波[2] 罗先蓉[2] 张小瑜[2] 周健[2] 

机构地区：[1]空军总医院呼吸内科,北京100036 [2]中国人民解放军第452医院呼吸内科,成都610021

出　　处：《中国医刊》2005年第5期47-48,共2页Chinese Journal of Medicine

摘　　要：目的　探讨COPD急性加重期(AECOPD)外周血中肿瘤坏死因子(TNF-α),白细胞介素6(IL-6)及分泌型IgA(SIgA)的变化及临床意义。方法　选择AECOPD患者30例(COPD组)抽静脉血,用顺序饱和液相竞争放射免疫分析法,测定血浆TNF-α的含量;用放射免疫分析技术测定血清中IL-6的含量;用竞争性放射免疫分析方法测定痰液中SIgA的含量,并与正常对照组(正常组)比较。结果　AECOPD组血浆TNF-α为(0. 49±0. 08)ng/ml,正常组为(0. 21±0. 03)ng/ml;血清IL 6:AECOPD组为(0. 89±0. 25)ng/ml,正常组为(0. 69±0. 11)ng/ml;痰液中SIgA、AECOPD与正常组分别为(536. 6±91. 1)μg/ml、(865. 09±183. 01)μg/ml,结果显示:AECOPDTNF α与IL-6均较正常组明显增高(IL 6P<0. 01,TNF-αP<0. 05),并伴心衰者TNF-α、IL-6水平较不伴心衰者高(IL-6P<0. 05,TNF-αP<0. 01),痰液中SIgA测值较正常组明显下降(P<0. 01)。结论　痰液中SIgA含量下降是COPD反复急性发作的重要原因,血中TNF-α、IL-6升高是肺部感染时的重要指标,并与疾病严重程度有关。Objective To investigate the change and clinical significance of IL-6 in serum and in sputa in the acute exacerbating COPD (AECOPD) patients. Methods Thirty AECOPD patients were selected as COPD group(c), thirty five normal people as healthy control group(H).All these cases were assayed separately IL-6, in serum and SIgA in sputa. Results The C group's TNF-α in serum averaged (0.49±0.08)ng/ml, and H group averaged(0.21±0.03)ng/ml, P<0.05 .The IL-6 in serum of C group averaged(0.89±0.25)ng/ml, H group averaged(0.69±0.11)ng/ml, P<0.01. The SIgA in sputa of C group averaged (536.6±91.1)μg/ml, H group averaged(865.09±183.00) μg/ml,(P<0.01. )Both TNF-α and IL-6 in serum of C group increased, and contrarily the SIgA in sputa lowered. Conclusion The level of increasing TNF-α and IL-6 in serum is an important indicator of pulmonary infection, and it′s also correlated with the critical level of COPD. On the other hand the level of decreasing SIgA in sputa is an important reason that results in COPD patients exacerbating repeatedly.

关 键 词：急性加重期 临床意义 肿瘤坏死因子(TNF-α) AECOPD 血浆TNF-Α 放射免疫分析方法 放射免疫分析法 COPD患者 免疫分析技术 血清IL-6 SIGA含量 疾病严重程度 白细胞介素 正常组 正常对照组 方法选择 0.05 急性发作 肺部感染 

分 类 号：R541.5[医药卫生—心血管疾病] R692[医药卫生—内科学]